Suppr超能文献

微小RNA作为急性肾损伤的生物标志物和治疗靶点

MicroRNAs as Biomarkers and Therapeutic Targets for Acute Kidney Injury.

作者信息

Tsuji Kenji, Nakanoh Hiroyuki, Fukushima Kazuhiko, Kitamura Shinji, Wada Jun

机构信息

Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.

Program in Membrane Biology, Center for Systems Biology, Department of Medicine, Division of Nephrology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.

出版信息

Diagnostics (Basel). 2023 Sep 9;13(18):2893. doi: 10.3390/diagnostics13182893.

Abstract

Acute kidney injury (AKI) is a clinical syndrome where a rapid decrease in kidney function and/or urine output is observed, which may result in the imbalance of water, electrolytes and acid base. It is associated with poor prognosis and prolonged hospitalization. Therefore, an early diagnosis and treatment to avoid the severe AKI stage are important. While several biomarkers, such as urinary L-FABP and NGAL, can be clinically useful, there is still no gold standard for the early detection of AKI and there are limited therapeutic options against AKI. miRNAs are non-coding and single-stranded RNAs that silence their target genes in the post-transcriptional process and are involved in a wide range of biological processes. Recent accumulated evidence has revealed that miRNAs may be potential biomarkers and therapeutic targets for AKI. In this review article, we summarize the current knowledge about miRNAs as promising biomarkers and potential therapeutic targets for AKI, as well as the challenges in their clinical use.

摘要

急性肾损伤(AKI)是一种临床综合征,表现为肾功能和/或尿量迅速下降,这可能导致水、电解质和酸碱平衡失调。它与预后不良和住院时间延长有关。因此,早期诊断和治疗以避免进入严重AKI阶段很重要。虽然几种生物标志物,如尿L-FABP和NGAL,在临床上可能有用,但目前仍没有早期检测AKI的金标准,且针对AKI的治疗选择有限。微小RNA(miRNA)是一类非编码单链RNA,在转录后过程中使靶基因沉默,并参与广泛的生物学过程。最近积累的证据表明,miRNA可能是AKI的潜在生物标志物和治疗靶点。在这篇综述文章中,我们总结了关于miRNA作为AKI有前景的生物标志物和潜在治疗靶点的现有知识,以及它们在临床应用中的挑战。

相似文献

1
MicroRNAs as Biomarkers and Therapeutic Targets for Acute Kidney Injury.
Diagnostics (Basel). 2023 Sep 9;13(18):2893. doi: 10.3390/diagnostics13182893.
2
Sepsis-Associated Acute Kidney Injury: Where Are We Now?
Medicina (Kaunas). 2024 Mar 6;60(3):434. doi: 10.3390/medicina60030434.
5
Current concepts and advances in biomarkers of acute kidney injury.
Crit Rev Clin Lab Sci. 2021 Aug;58(5):354-368. doi: 10.1080/10408363.2021.1879000. Epub 2021 Feb 8.
6
MicroRNA as an early diagnostic biomarker for contrast-induced acute kidney injury.
Drug Chem Toxicol. 2022 Jul;45(4):1552-1557. doi: 10.1080/01480545.2020.1846550. Epub 2020 Nov 16.
7
Performance of Serum Creatinine and Kidney Injury Biomarkers for Diagnosing Histologic Acute Tubular Injury.
Am J Kidney Dis. 2017 Dec;70(6):807-816. doi: 10.1053/j.ajkd.2017.06.031. Epub 2017 Aug 24.
8
Update on biomarkers of acute kidney injury: moving closer to clinical impact?
Mol Diagn Ther. 2012 Aug 1;16(4):199-207. doi: 10.1007/BF03262209.

引用本文的文献

2
From bench to bedside: translating mesenchymal stem cell therapies through preclinical and clinical evidence.
Front Bioeng Biotechnol. 2025 Jul 30;13:1639439. doi: 10.3389/fbioe.2025.1639439. eCollection 2025.
4
Analysis of key microRNA molecules associated with acute kidney injury based on bioinformatics method.
Medicine (Baltimore). 2025 Mar 7;104(10):e41785. doi: 10.1097/MD.0000000000041785.
5
Evaluation of microRNA-10a and microRNA-210 as Biomarkers in Sepsis Patients With Acute Kidney Injury.
Int J Nephrol. 2024 Dec 12;2024:1555811. doi: 10.1155/ijne/1555811. eCollection 2024.
7
Fecal miRNAs as potential biomarkers for early detection of colorectal cancer: An updated review.
Biomed J. 2025 Feb;48(1):100769. doi: 10.1016/j.bj.2024.100769. Epub 2024 Jul 17.

本文引用的文献

1
MicroRNA: trends in clinical trials of cancer diagnosis and therapy strategies.
Exp Mol Med. 2023 Jul;55(7):1314-1321. doi: 10.1038/s12276-023-01050-9. Epub 2023 Jul 10.
2
Proficient Novel Biomarkers Guide Early Detection of Acute Kidney Injury: A Review.
Diseases. 2022 Dec 30;11(1):8. doi: 10.3390/diseases11010008.
4
One microRNA has the potential to target whole viral mRNAs in a given human coronavirus.
Front Microbiol. 2022 Nov 10;13:1035044. doi: 10.3389/fmicb.2022.1035044. eCollection 2022.
5
Circulating MicroRNAs as Cancer Biomarkers in Liquid Biopsies.
Adv Exp Med Biol. 2022;1385:23-73. doi: 10.1007/978-3-031-08356-3_2.
6
A perspective on oligonucleotide therapy: Approaches to patient customization.
Front Pharmacol. 2022 Oct 19;13:1006304. doi: 10.3389/fphar.2022.1006304. eCollection 2022.
7
Advances in the study of subclinical AKI biomarkers.
Front Physiol. 2022 Aug 24;13:960059. doi: 10.3389/fphys.2022.960059. eCollection 2022.
8
miR-181a-5p Inhibits Pyroptosis in Sepsis-Induced Acute Kidney Injury through Downregulation of NEK7.
J Immunol Res. 2022 Aug 10;2022:1825490. doi: 10.1155/2022/1825490. eCollection 2022.
9
MicroRNAs in kidney injury and disease.
Nat Rev Nephrol. 2022 Oct;18(10):643-662. doi: 10.1038/s41581-022-00608-6. Epub 2022 Aug 16.
10
miR-22 alleviates sepsis-induced acute kidney injury via targeting the HMGB1/TLR4/NF-κB signaling pathway.
Int Urol Nephrol. 2023 Feb;55(2):409-421. doi: 10.1007/s11255-022-03321-2. Epub 2022 Aug 12.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验